Pluto Bioinformatics

GSE95771: AG221 and Ruxolitinib Treatment Effects on LSKs in IDH2-R140Q JAK2-V617F Transplant Recipients

Bulk RNA sequencing

Transplant recipients of IDH2-R140Q JAK2-V617F expressing bone marrow were treated with AG221 and ruxolitinib monotherapy, combined therapy, or vehicle. LSKs were sorted from terminal samples and sequenced with three WT controls. SOURCE: Barbara Spitzer (spitzerb@mskcc.org) - Levine Lab Memorial Sloan Kettering Cancer Center